Under the abbreviated 505(b)(2) pathway, Liquidia Technologies (NASDAQ:LQDT) has submitted a
marketing application to the FDA seeking approval for an inhaled dry
powder formulation of treprostinil for the treatment of pulmonary
arterial hypertension.
Treprostinil, administered intravenously or subcutaneously, is marketed under the brand name Remodulin by United Therapeutics. It markets an inhalable solution formulation under the brand name Tyvaso.
Shares down 6% premarket on light volume.
https://seekingalpha.com/news/3534651-liquidia-files-u-s-application-for-inhaled-formulation-of-treprostinil
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.